“Small molecules” drug belonging to a class or pharmaceutical agents called anti-angiogenics are novel anti-cancer drugs developed by the University of Minnesota to treat solid tumors.
These new compounds are refined form of drugs that effectively reduce blood flow to the tumor, thereby inhibiting tumor growth.
"This is a novel class of drugs that increases the potential for good, effective treatment for cancer patients with tumors," said Kevin Mayo, Ph.D., principle investigator and professor of biochemistry, molecular biology and biophysics at the University of Minnesota Medical School.
Currently, there is a USFDA-approved protein anti-angiogenic agent and University of Minnesota’s new tumor-targeting compounds were designed to mimic the functional part of an anti-angiogenic protein and has the advantage of potentially being taken in pill form (because it is not a protein in itself), thereby will cost less to produce.
These study results appear in the July 5 issue of the Journal of the National Cancer Institute.
Read more at EurekAlert.
.jpg)
Comment Preview